In Vivo Tumor Vasculature Targeting and Imaging with Vegf-Conjugated Nanographene Oxide
Sixiang Shi,Kai Yang,Hao Hong,Robert Nickles,Zhuang Liu,Weibo Cai
2014-01-01
Journal of Nuclear Medicine
Abstract:1371 Objectives Because of their unique properties including large surface area, versatile chemistry, and low toxicity, graphene-based materials are versatile platforms for cancer imaging and therapy. Our goal was to employ nanographene oxide (GO) for in vivo tumor vasculature targeting, and to quantitatively evaluate the tumor targeting efficacy with PET using 64Cu as the radiolabel. Methods GO sheets, with amino group-terminated branched PEG covalently attached to the surface, were conjugated to NOTA (for 64Cu labeling) and VEGF121 (a naturally occurring protein that bind to VEGFR, a vascular marker of tumor angiogenesis). NOTA conjugated GO, without VEGF121, was also synthesized as the control. FACS analysis, size measurements, and serum stability studies were performed to characterize the GO conjugates. Serial PET imaging and biodistribution studies were carried out to evaluate the tumor targeting efficacy and pharmacokinetics in xenograft U87MG tumor-bearing mice, which express high level of VEGFR on the tumor vasculature but not on the tumor cells. Imaging results were validated by histology. Results NOTA-GO-VEGF121 had sizes of ~20-100 nm and exhibited VEGFR specificity and superb stability in vitro and in vivo. Serial PET imaging showed rapid and persistent uptake of 64Cu-NOTA-GO-VEGF121 (6.5±1.7, 8.2±1.4, 7.7±1.4, 5.7±0.8, and 4.7±0.7 %ID/g at 0.5, 3, 6, 16, and 24 post-injection; n=4) in U87MG tumor, several fold higher than non-targeted control (i.e. 64Cu-NOTA-GO), which was confirmed by bio-D. Flow cytometry and histological examination confirmed the specificity of 64Cu-NOTA-GO-VEGF121 for tumor vascular VEGFR targeting, with little extravasation. Conclusions 64Cu-NOTA-GO-VEGF121 was able to target vascular VEGFR efficiently in mouse models, which gave an extra boost to tumor uptake based on passive targeting alone. The significantly improved tumor targeting efficiency of GO realized in this work may be utilized for future PET image-guided cancer-targeted drug/gene delivery in vivo, to further enhance the therapeutic efficacy and to enable cancer theranostics.